Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Phase II Trial Evaluating the Efficacy and Safety of RBD5044 in Chinese Participants With Hypertriglyceridemia

NCT07587788 is registered in ClinicalTrials.gov with Ribotek Biopharmaceuticals (Shandong) Co., Ltd as lead sponsor.

NCT NCT07587788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07587788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-Blind, Placebo-Controlled Phase II Trial Evaluating the Efficacy and Safety of RBD5044 in Chinese Participants With Hypertriglyceridemia
Lead sponsor
Ribotek Biopharmaceuticals (Shandong) Co., Ltd
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 28, 2026
Completion date
March 31, 2027
Enrollment
40 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia